186 related articles for article (PubMed ID: 18160667)
1. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Raponi M; Lancet JE; Fan H; Dossey L; Lee G; Gojo I; Feldman EJ; Gotlib J; Morris LE; Greenberg PL; Wright JJ; Harousseau JL; Löwenberg B; Stone RM; De Porre P; Wang Y; Karp JE
Blood; 2008 Mar; 111(5):2589-96. PubMed ID: 18160667
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
Rolland D; Ribrag V; Haioun C; Ghesquieres H; Jardin F; Bouabdallah R; Franchi P; Briere J; De Kerviler E; Chassagne-Clement C; Raponi M; Houlgatte R; Jais JP; Thieblemont C
Cancer Chemother Pharmacol; 2010 Mar; 65(4):781-90. PubMed ID: 19960345
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors: where are we now?
Tsimberidou AM; Chandhasin C; Kurzrock R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1569-80. PubMed ID: 21083522
[TBL] [Abstract][Full Text] [Related]
4. Tipifarnib in acute myeloid leukemia.
Burnett AK; Kell J
Drugs Today (Barc); 2007 Nov; 43(11):795-800. PubMed ID: 18174965
[TBL] [Abstract][Full Text] [Related]
5. Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
Raponi M; Harousseau JL; Lancet JE; Löwenberg B; Stone R; Zhang Y; Rackoff W; Wang Y; Atkins D
Clin Cancer Res; 2007 Apr; 13(7):2254-60. PubMed ID: 17404110
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.
Ding H; McDonald JS; Yun S; Schneider PA; Peterson KL; Flatten KS; Loegering DA; Oberg AL; Riska SM; Huang S; Sinicrope FA; Adjei AA; Karp JE; Meng XW; Kaufmann SH
Haematologica; 2014 Jan; 99(1):60-9. PubMed ID: 23996484
[TBL] [Abstract][Full Text] [Related]
7. Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Erba HP; Othus M; Walter RB; Kirschbaum MH; Tallman MS; Larson RA; Slovak ML; Kopecky KJ; Gundacker HM; Appelbaum FR
Leuk Res; 2014 Mar; 38(3):329-33. PubMed ID: 24411921
[TBL] [Abstract][Full Text] [Related]
8. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Karp JE; Vener TI; Raponi M; Ritchie EK; Smith BD; Gore SD; Morris LE; Feldman EJ; Greer JM; Malek S; Carraway HE; Ironside V; Galkin S; Levis MJ; McDevitt MA; Roboz GR; Gocke CD; Derecho C; Palma J; Wang Y; Kaufmann SH; Wright JJ; Garret-Mayer E
Blood; 2012 Jan; 119(1):55-63. PubMed ID: 22001391
[TBL] [Abstract][Full Text] [Related]
9. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Goemans BF; Zwaan CM; Harlow A; Loonen AH; Gibson BE; Hählen K; Reinhardt D; Creutzig U; Heinrich MC; Kaspers GJ
Blood; 2005 Nov; 106(10):3532-7. PubMed ID: 16051737
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
11. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
Epling-Burnette PK; Loughran TP
Expert Opin Investig Drugs; 2010 May; 19(5):689-98. PubMed ID: 20402600
[TBL] [Abstract][Full Text] [Related]
12. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
Raponi M; Belly RT; Karp JE; Lancet JE; Atkins D; Wang Y
BMC Cancer; 2004 Aug; 4():56. PubMed ID: 15329151
[TBL] [Abstract][Full Text] [Related]
13. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
van der Weide K; de Jonge-Peeters SD; Kuipers F; de Vries EG; Vellenga E
Clin Cancer Res; 2009 May; 15(9):3076-83. PubMed ID: 19383813
[TBL] [Abstract][Full Text] [Related]
14. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
Yanamandra N; Buzzeo RW; Gabriel M; Hazlehurst LA; Mari Y; Beaupre DM; Cuevas J
J Pharmacol Exp Ther; 2011 Jun; 337(3):636-43. PubMed ID: 21378206
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Harousseau JL; Lancet JE; Reiffers J; Lowenberg B; Thomas X; Huguet F; Fenaux P; Zhang S; Rackoff W; De Porre P; Stone R;
Blood; 2007 Jun; 109(12):5151-6. PubMed ID: 17351110
[TBL] [Abstract][Full Text] [Related]
16. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.
Emadi A; Karp JE
Pharmacogenomics; 2012 Aug; 13(11):1257-69. PubMed ID: 22920396
[TBL] [Abstract][Full Text] [Related]
17. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Medeiros BC; Landau HJ; Morrow M; Lockerbie RO; Pitts T; Eckhardt SG
Leukemia; 2007 Apr; 21(4):739-46. PubMed ID: 17268526
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Lancet JE; Gojo I; Gotlib J; Feldman EJ; Greer J; Liesveld JL; Bruzek LM; Morris L; Park Y; Adjei AA; Kaufmann SH; Garrett-Mayer E; Greenberg PL; Wright JJ; Karp JE
Blood; 2007 Feb; 109(4):1387-94. PubMed ID: 17082323
[TBL] [Abstract][Full Text] [Related]
19. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
20. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
Luger SM; Wang VX; Rowe JM; Litzow MR; Paietta E; Ketterling RP; Lazarus H; Rybka WB; Craig MD; Karp J; Cooper BW; Makary AZ; Kaminer LS; Appelbaum FR; Larson RA; Tallman MS
Leuk Res; 2021 Dec; 111():106736. PubMed ID: 34773794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
